Brand Reference: Actos
| Metric | Verified Benchmark | Source |
|---|---|---|
| Pioglitazone Hydrochloride RxNorm Concept ID | 33738 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0950 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $48.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $6.90 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $9.20 / mo | 14 Zero-PHI Verified Patient Logs |
Selectively activates peroxisome proliferator-activated receptor gamma (PPAR-gamma) nuclear transcription factors in adipocytes, skeletal muscle, and hepatocytes, upregulating adiponectin, redistributing ectopic hepatic/visceral fat into subcutaneous depots, and enhancing peripheral insulin sensitivity.
Across 14 community cost disclosures for Pioglitazone Hydrochloride (Actos), cash buyers routing around $48.00 retail markups capture a 86% discount ($6.90/mo benchmark vs $0.0950 NADAC acquisition).
Following administration (15 mg PO once daily), Pioglitazone Hydrochloride achieves > 80% oral bioavailability and 2–4 weeks initial; maximal hba1c shift at 10–12 weeks onset, governed by a 3–7 hours parent / 16–24 hours active metabolites terminal half-life through hepatic hydroxylation and oxidation via cyp2c8 and cyp3a4 to active m-iii and m-iv.
Before initiating Pioglitazone Hydrochloride at 15 mg PO once daily, clinical safety checklists rule out nyha class iii or iv heart failure; active urothelial bladder carcinoma; decompensated hepatic transaminitis. Logged tolerability patterns center on subcutaneous weight gain (19% of reports), mild pedal edema (16% of reports), fluid retention (11% of reports).
Across 14 verified cash-pay logs, Pioglitazone Hydrochloride achieves a 80.50% Worth-It rating with out-of-pocket spend averaging $9.20/mo versus $48.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 15 mg PO once daily for Pioglitazone Hydrochloride; monthly out-of-pocket dropped to $6.07 compared with $48.00 retail.
Completed 10 weeks on Pioglitazone Hydrochloride (30 mg PO once daily). Zero notable side effects on steady dosing.
Consistent biomarker response on 45 mg PO once daily Pioglitazone Hydrochloride sourced via Cost Plus Drugs ($8.00/mo cash pay without insurance prior authorization).